Hsa-mir-377 targets ETS1 to inhibit human clear cell renal cell carcinoma 38, targets E2F3 to inhibit non-small cell lung cancer 39, and targets BRD4 to inhibit colon cancer 40. Here, E2F3 is linked to colonic neoplasm.